Melinta Therapeutics

It is already the last day of Making a Difference in Infectious Diseases 2024 (#MADID2024) here at the Omni Orlando Resort at ChampionsGate! Be sure to drop by booth 501 before you go. See you next year!

Welcome to Day 3 of the 26th Annual MAD-ID Meeting, The Antimicrobial Stewardship Meeting® (#MADID2024). We are exhibiting live at booth 501; join us in Orlando and meet the Melinta team.

Melinta is in Orlando, FL at MAD-ID 2024, The Antimicrobial Stewardship Meeting®. Visit us at booth 501 today through May 11th. #MADID2024

Melinta Celebrates National Nurses Week! This week, we honor the incredible nurses whose dedication and compassion underpin our healthcare system. Your resilience and bravery, especially in recent challenging times, have not gone unnoticed. Thank you for your unwavering commitment to patient care. Let’s all take a moment to appreciate the invaluable contributions of nurses everywhere. Your hard work inspires us all! #NationalNursesWeek #HealthcareHeroes #ThankYouNurses

We are excited to exhibit here at MAD-ID 2024 in Orlando, FL. Stop by booth 501 and meet the Melinta Team!

Melinta will be live at the 26th Annual MAD-ID Meeting #MADID2024! Join us at the Omni Orlando Resort at ChampionsGate and stop by booth 501 from May 8th to 11th.

At Melinta Therapeutics, our mission is to provide innovative therapies to people impacted by acute and life-threatening illnesses. That’s why a new study published last week in the Annals of Internal Medicine caught our attention. The study found that, from 2016 to 2021, despite 7 next generation antibiotics being approved and marketed in the US more than 40% of patients at US hospitals who had infections with difficult-to-treat resistant (DTR) organisms were treated exclusively with older traditional generic antibiotics. Four of 5 times, these older agents had known suboptimal safety and/or efficacy profiles. According to the study's authors, their findings, "...have implications for both prescribing clinicians hoping to optimize management of DTR infections and antibiotic-resistance stakeholders hoping to fix the broken antibiotic market.” Last July, Christine Ann Miller, President and CEO, Melinta Therapeutics gave testimony before the U.S. Senate Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Miller shared her belief that we will continue to see further deterioration of the anti-infective innovation pipeline if we continue to do nothing “Patients – grandmothers, children, fathers, mothers, our neighbors – will continue to die,” Miller told the Subcommittee characterizing the issue as a commercial marketplace problem – driven by reimbursement and access challenges – that is fundamentally unique to antimicrobials. “Without reforms on the post-approval side of the equation to increase access to new antibiotics – through reforms to antimicrobial reimbursement and novel payment mechanisms called ‘pull incentives’ that decouple payment from the volume of antimicrobials used – hospitals will continue to be forced to rely on older medications.” Read the full testimony: https://lnkd.in/eyurtmuN. To find out more about Melinta Therapeutics and our products, visit our website: Melinta.com.

Happy Administrative Professionals Day to all the incredible individuals who, day in and day out, help drive our Melinta mission forward! Your hard work, dedication, and attention to detail are the backbone of our success. Thank you for all that you do to support our teams and make our workplace a better place. Your contributions are truly appreciated and valued! #AdministrativeProfessionalsDay #ThankYou #MelintaEmployee #BestTeamEver

It is already the last day of the American Case Management Association 2024 National Conference here in Nashville! Be sure to drop by booth 607 before you go. See you next year! #ACMA24 #ACMAnational

Melinta is in Nashville, TN at the 2024 ACMA National Conference. Visit us in booth 607 today thru April 22nd. #ACMAnational #ACMA24